Login to Your Account



Valuing Ranexa

CVT Rejects $1B Acquisition Offer from Partner Astellas

By Trista Morrison


Wednesday, January 28, 2009
Astellas Pharma Inc. revealed Tuesday that it has spent the last year attempting to acquire CV Therapeutics Inc., but the biotech rejected its latest $1 billion offer and declined to engage in further discussions. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription